Trends in Buprenorphine Prescribing for Opioid Use Disorder by Psychiatrists in the US From 2003 to 2021

Timothy B Creedon; Mir M Ali; Zev Schuman-Olivier

doi:10.1001/jamahealthforum.2023.0221

Trends in Buprenorphine Prescribing for Opioid Use Disorder by Psychiatrists in the US From 2003 to 2021

JAMA Health Forum. 2023 Apr 7;4(4):e230221. doi: 10.1001/jamahealthforum.2023.0221.

Authors

Timothy B Creedon¹, Mir M Ali¹, Zev Schuman-Olivier^{2

3}

Affiliations

¹ Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Washington, DC.
² Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
³ Center for Mindfulness and Compassion, Cambridge Health Alliance, Cambridge, Massachusetts.

No abstract available

Plain language summary

This cross-sectional study uses data from a database to compare national trends in patients treated with buprenorphine by psychiatrists and nonpsychiatrists from 2003 to 2021.

Publication types

Letter

MeSH terms

Buprenorphine* / therapeutic use
Humans
Narcotic Antagonists / therapeutic use
Opioid-Related Disorders* / drug therapy
Opioid-Related Disorders* / epidemiology
Psychiatry*

Substances

Buprenorphine
Narcotic Antagonists